WhatsApp Image 2020-07-31 at 10.09.02 AM

why India Will Remain a central Player in the development of Vaccine – Free PDF


THE STORY SO FAR

  • 25 candidate vaccines in human trials
  • Five in Stage-III trials
  • Pfizer-BioNTech vaccine to carry out Stage-II an Stage-III simultaneously
  • 139 candidates in pre-clinical trial stage
  • Two Indian candidates in Stage-I trials

INDIA ONE OF THE LARGEST PRODUCERS OF VACCINES

  • Irrespective of how the vaccine candidates developed by Indian companies eventually perform, India would remain a central player, both as one of the biggest manufacturers of vaccines in the world, and also one of the biggest markets. India controls nearly 60 per cent of the global supply of all kinds of vaccines.


VACCINES

  • Pune-based Serum Institute of India happens to be the largest manufacturer of vaccines in the world, and the company has entered an agreement to produce the vaccine being developed by Oxford University and AstraZeneca.
  • There are several other Indian pharmaceutical and biotechnology companies that are prominent players in the production and supply of vaccines.
  • Hyderabad-based Bharat Biotech, which is developing its own vaccine as well, Panacea Biotech, Shanta Biotech, Biological E Limited, are some of the other big names with large production capacities.


VACCINES

  • Irrespective of which vaccine gets ready first, a bulk of the production is likely to happen in India. These companies already have hold over a substantial chunk of the foreign markets. And this is likely to be more so during the current pandemic due to increasing distrust for Chinese companies in several countries, which are the biggest rivals.
  • Besides, as the second-most populous country in the world, India also happens to be one of the biggest markets for vaccines.


Moderna Therapeutics begins phase-III trials

  • The one being developed by US-based Moderna Therapeutics was the earliest mover, its phase-I human trials having started as early as middle of March.
  • It has now completed phase-I and phase-II trials and, on Monday, entered phase-III trials, for which 30,000 volunteers have been roped in. They go about their normal lives, and after a few weeks, they are checked to see if they have been infected.


Moderna Therapeutics begins phase-III trials

  • Researchers expect to see a significantly lower infection rate in the group that was given the vaccine. This process usually takes several months.
  • The phase 3 of Moderna, technically, will complete in October 2022. However, whether the vaccine candidate will make the cut and become one of the first vaccines to be launched commercially early next year will depend largely on the preliminary data on efficacy, safety and immunogenicity that will emerge after the second dose is given to the volunteers on day 29 of the trials.
  •  Also, the levels of neutralising antibodies, that render the virus inactive, generated between day 1 and day 57, will be the most crucial data that researchers will closely watch.


Gennova to be third Indian firm to bring vaccine candidate

  • Pune-based Gennova Biopharmaceuticals is planning to start testing its candidate vaccine on human beings by October. Right now it is carrying out pre-clinical trials.
  •  Two Indian candidates have just begun phase-I clinical trials earlier this month. One of them is being developed by Hyderabad-based Bharat Biotech, in collaboration with Pune-based National Institute of Virology, which is part of the network of laboratories of the Indian Council of Medical Research.
  •  The other one is being developed by Ahmedabad-based Zydus Cadila.

 

 

Latest Burning Issues | Free PDF